Archer Materials (ASX:AXE) integrated its graphene field effect transistor sensors with electrical readout circuitry in a new chip as it seeks to integrate the Biochip into an at-home testing device for
chronic kidney disease, according to a Thursday ASX filing.
The chips were fabricated at foundry partner VTT Technical Research Centre of Finland via a multi-project wafer run on a 200mm wafer. Chips from the wafer are being packaged for testing at the firm.
It will continue the integration work in parallel with the ongoing development of the Biochip. The Biochip development and integration activities will be targeted at having early prototypes of the system and demonstration of initial potassium testing accuracy performance early in 2026.
The Biochip needs to be integrated with cartridge fluidics for the delivery of the blood sample for sensing. Integrating the Biochip with miniaturized electronics is a key step in this regard.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。